In recent years a real revolution in the field of immunotherapy both in cancer and other diseases has happened globally. Immunotherapeutic strategies, including immune checkpoint inhibitors, adoptive cell therapies and monoclonal antibodies have dramatically impacted on cancer treatment and patients' outlook. However, only a limited number of therapeutic and diagnostic targets are clinically in use hindering the great potential of translational discoveries into clinical benefit through molecular biology technologies. In particular, NSG-based approaches applied to B and T-cell receptor repertoire analysis allow for the development of innovative immunotherapies based on chimeric antigen receptor (CAR), engineered antibodies, conjugated antibody fragments or bispecific antibodies offering novel therapeutic options against infectious diseases, autoimmune diseases and cancer.
Today, molecular tools enable researchers, more than in the past, to prospectively identify novel immunotherapies and test their efficacy on preclinical models of disease and human tissues/samples. Those activities find application in the development of clinically relevant immunotherapies in different disease settings from autoimmune, infectious disease to cancer. The goal of this Research Topic is to recapitulate the state-of-the-art on the approaches used to generate or develop relevant immunotherapies. It also aims at providing an up-to-date overview of the growing field of antibodies and immune receptor repertoire analysis.
The Research Topic on ‘’New Avenues for the Development of Advanced Immunotherapies: Capitalizing on Studies of the B and T Cell Receptor Repertoire” aims to provide an up-to-date overview of the growing field of molecular immunology and downstream immunotherapy development, including:
● Description of methods for the identification and development of antibodies and derived molecules (ScFv, VHH) as well as TCRs towards unknown or novel targets
● Description of methods for antibody and TCR antigens identification
● Generation of T- / B- cell receptor repertoire repositories from exposed individuals and patients
● Proof of concept studies with preclinical evidence for specific immunotherapies and diagnostics (e.g. CAR and TCR against specific targets, ADC, BiTEs, theranostics, companion diagnostics)
We believe that the use of advanced tools such as NGS applied to screening strategies or to describe the complexity of immunological receptors in vivo, will open up a new era for the development of more effective immunotherapies in several pathological contexts.
We look forward to receiving contributions like original articles or reviews on the subject.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords:
Antibody identification and engineering, immunotherapy, bi-specific antibodies, CAR-T cells, TCR/ BCR repertoire study
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
In recent years a real revolution in the field of immunotherapy both in cancer and other diseases has happened globally. Immunotherapeutic strategies, including immune checkpoint inhibitors, adoptive cell therapies and monoclonal antibodies have dramatically impacted on cancer treatment and patients' outlook. However, only a limited number of therapeutic and diagnostic targets are clinically in use hindering the great potential of translational discoveries into clinical benefit through molecular biology technologies. In particular, NSG-based approaches applied to B and T-cell receptor repertoire analysis allow for the development of innovative immunotherapies based on chimeric antigen receptor (CAR), engineered antibodies, conjugated antibody fragments or bispecific antibodies offering novel therapeutic options against infectious diseases, autoimmune diseases and cancer.
Today, molecular tools enable researchers, more than in the past, to prospectively identify novel immunotherapies and test their efficacy on preclinical models of disease and human tissues/samples. Those activities find application in the development of clinically relevant immunotherapies in different disease settings from autoimmune, infectious disease to cancer. The goal of this Research Topic is to recapitulate the state-of-the-art on the approaches used to generate or develop relevant immunotherapies. It also aims at providing an up-to-date overview of the growing field of antibodies and immune receptor repertoire analysis.
The Research Topic on ‘’New Avenues for the Development of Advanced Immunotherapies: Capitalizing on Studies of the B and T Cell Receptor Repertoire” aims to provide an up-to-date overview of the growing field of molecular immunology and downstream immunotherapy development, including:
● Description of methods for the identification and development of antibodies and derived molecules (ScFv, VHH) as well as TCRs towards unknown or novel targets
● Description of methods for antibody and TCR antigens identification
● Generation of T- / B- cell receptor repertoire repositories from exposed individuals and patients
● Proof of concept studies with preclinical evidence for specific immunotherapies and diagnostics (e.g. CAR and TCR against specific targets, ADC, BiTEs, theranostics, companion diagnostics)
We believe that the use of advanced tools such as NGS applied to screening strategies or to describe the complexity of immunological receptors in vivo, will open up a new era for the development of more effective immunotherapies in several pathological contexts.
We look forward to receiving contributions like original articles or reviews on the subject.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords:
Antibody identification and engineering, immunotherapy, bi-specific antibodies, CAR-T cells, TCR/ BCR repertoire study
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.